Bio-Techne Corporation Bio-Techne Corporation

Bio-Techne Corporation

TECH

Pozycja w akcjach #1872
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures,... Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Cena akcji
$72.55
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$11.38B
Zmiana (1 dzień)
0.03%
Zmiana (1 rok)
17.27%
Kraj
US
Handel Bio-Techne Corporation (TECH)

Kategoria

Healthcare
Zyski dla Bio-Techne Corporation (TECH)
Zyski w Jun 2026 TTM: $240.68M
Według najnowszych raportów finansowych Bio-Techne Corporation, obecny zysk firmy wynosi $240.68M. W roku 2024 firma osiągnęła zysk w wysokości $185.69M, spadek w porównaniu do zysku z roku 2023, który wynosił $338.66M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Bio-Techne Corporation od 2000 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
2026 (TTM) $240.68M 144.44%
2025 $98.46M -46.97%
2024 $185.69M -45.17%
2023 $338.66M 12.37%
2022 $301.39M 103.40%
2021 $148.18M -46.41%
2020 $276.48M 146.82%
2019 $112.02M -11.07%
2018 $125.95M 11.30%
2017 $113.16M -23.27%
2016 $147.48M -4.33%
2015 $154.16M -4.48%
2014 $161.39M 0.45%
2013 $160.66M -0.95%
2012 $162.20M -1.69%
2011 $164.98M 5.46%
2010 $156.45M 0.70%
2009 $155.36M 1.00%
2008 $153.83M 19.31%
2007 $128.93M 15.98%
2006 $111.16M 11.29%
2005 $99.89M 21.02%
2004 $82.54M 18.67%
2003 $69.56M 84.32%
2002 $37.74M -21.07%
2001 $47.81M 21.30%
2000 $39.41M 0.00%
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
$5.27B 2,091.67%
US
$-3.09B -1,382.62%
US
$-4.02B -1,768.69%
AU
- -
CH
$1.95B 710.47%
NL